{"filing":{"accession_number":"0001193125-26-342669","cik":"0001761918","ticker":"ERAS","company_name":"Erasca, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"eras-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/eras-20260810.htm"},"events":[{"id":26726,"run_id":24301,"accession_number":"0001193125-26-342669","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Dr. Charles S. Fuchs was appointed President, Research \u0026 Development of Erasca, Inc., effective August 10, 2026. This is a material executive appointment of a senior officer with significant oncology and biopharmaceutical development experience, including prior roles at Roche/Genentech and Yale Cancer Center. The appointment includes substantial compensation (base salary $570,000, 45% bonus target, and 1.3 million stock options), making it material to investors' assessment of the company's leadership and strategic direction.","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27948,"accession_number":"0001193125-26-342669","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Charles S. Fuchs was appointed President, Research \u0026 Development of Erasca, Inc., effective August 10, 2026. This is a material executive appointment of a senior officer with significant oncology and biopharmaceutical development experience, including prior roles at Roche/Genentech and Yale Cancer Center. The appointment includes substantial compensation (base salary $570,000, 45% bonus target, and 1.3 million stock options), making it material to investors' assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:07:16.150804+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27948,"accession_number":"0001193125-26-342669","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Charles S. Fuchs was appointed President, Research \u0026 Development of Erasca, Inc., effective August 10, 2026. This is a material executive appointment of a senior officer with significant oncology and biopharmaceutical development experience, including prior roles at Roche/Genentech and Yale Cancer Center. The appointment includes substantial compensation (base salary $570,000, 45% bonus target, and 1.3 million stock options), making it material to investors' assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:07:16.150804+00:00","company_name":"Erasca, Inc.","ticker":"ERAS","filing_date":"2026-08-10"}]}